About ZOSTAVAX

ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia. ZOSTAVAX should not be used for prevention of primary varicella infection (Chickenpox).

Select Safety Information for ZOSTAVAX® (Zoster Vaccine Live)

Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients.

ZOSTAVAX is contraindicated in: persons with a history of anaphylactic or anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine; persons with a history of primary or acquired immunodeficiencies; persons on immunosuppressive therapy; pregnant women or women of childbearing age.

A reduced immune response to ZOSTAVAX was observed in individuals who received concurrent administration of PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks.

Serious vaccine-related adverse reactions that have occurred following vaccination with ZOSTAVAX include asthma exacerbation and polymyalgia rheumatica. Other serious adverse events reported following vaccination with ZOSTAVAX include cardiovascular events (congestive heart failure, pulmonary edema). Common adverse reactions occurring in ≥1% of vaccinated individuals during clinical trials include injection-site reactions (erythema, pain/tenderness, swelling, hematoma, pruritus, warmth) and headache.

Transmission of vaccine virus may occur between vaccinees and susceptible contacts.

Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis.

Before administering ZOSTAVAX® (Zoster Vaccine Live), please read the Prescribing Information. The Patient Information also is available.

1. Lu P-J, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009;27(6):882–887.
2. Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.
3. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Medicine. 2010;8:37.
4. Centers for Disease Control and Prevention (CDC). Surveillance of Vaccination Coverage Among Adult Populations – United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(1):1–37.
5. Data available on request from Merck, Professional Services–DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1114218-0002.
6. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1155684-0000.
7. Gallup Web site. Honesty/ethics in professions, December 2–6, 2015. http://www.gallup.com/poll/1654/honesty-ethics-professions.aspx. Accessed December 16, 2016.
8. Hess R. Impact of automated telephone messaging on zoster vaccination rates in community pharmacies. J Am Pharm Assoc. 2013;53(2):182–187.
9. National Foundation for Infectious Diseases. Call to Action: Adult Vaccination Saves Lives. Bethesda, MD: National Foundation for Infectious Diseases; 2012. http://www.adultvaccination.org/resources/cta-adult.pdf. Accessed December 16, 2016.
10. Data available on request from Merck, Professional Services–DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1114216-0002.

Reimbursement

Private Insurance
Private insurance = Medical benefit

When covered by private insurance, ZOSTAVAX is most often covered as a medical benefit. In such cases, the reimbursement process is similar to that of other vaccines and most other services.a

~98%
of privately insured patients aged ≥60 years are in plans that have approved reimbursement for ZOSTAVAX as of August 20155,b
Location can matter—

When vaccinating privately insured patients in a physician's office, their out-of-pocket costs may be less versus at a pharmacy that does not adjudicate private medical claims

IN FACT: ~8 out of 10 have $0 co-pay for ZOSTAVAX as of October 20156,c

Whether reimbursement is available for a specific patient depends on the patient's benefit design, including applicable co-pays, coinsurance, and/or deductions.
Get plan-specific information. Visit the Reimbursement Support section.

aFor patients who are aged ≥65 years with private insurance, some secondary medical insurers may require a denial from Medicare Part B. Check with the relevant insurer for their process.

bData provided by DR/Decision Resources, LLC, and current as of August 2015. (© DR/Decision Resources, LLC. All Rights Reserved.)

cData provided by Avalere Health ®. (© Avalere Health®. All Rights Reserved.)

Medicare Part D
Medicare Part D = Prescription benefit

For patients aged ≥65 years with Medicare who have opted into a Part D prescription drug plan, ZOSTAVAX is reimbursable as a prescription drug benefit and adjudicated as a prescription claim in the pharmacy.

Prescribe ZOSTAVAX and send your eligible Medicare Part D patients to a vaccinating pharmacy

Learn more about referring patients aged ≥65 years to the pharmacy

Location can matter—

Vaccinating Part D patients in the pharmacy may be more convenient for patients, and their out-of-pocket costs may be less (versus a physician's office that does not electronically adjudicate Part D claims) because Part D claims can be adjudicated electronically and in real-time in the pharmacy

About ZOSTAVAX

ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia. ZOSTAVAX should not be used for prevention of primary varicella infection (Chickenpox).

Select Safety Information for ZOSTAVAX® (Zoster Vaccine Live)

Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients.

ZOSTAVAX is contraindicated in: persons with a history of anaphylactic or anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine; persons with a history of primary or acquired immunodeficiencies; persons on immunosuppressive therapy; pregnant women or women of childbearing age.

A reduced immune response to ZOSTAVAX was observed in individuals who received concurrent administration of PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks.

Serious vaccine-related adverse reactions that have occurred following vaccination with ZOSTAVAX include asthma exacerbation and polymyalgia rheumatica. Other serious adverse events reported following vaccination with ZOSTAVAX include cardiovascular events (congestive heart failure, pulmonary edema). Common adverse reactions occurring in ≥1% of vaccinated individuals during clinical trials include injection-site reactions (erythema, pain/tenderness, swelling, hematoma, pruritus, warmth) and headache.

Transmission of vaccine virus may occur between vaccinees and susceptible contacts.

Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis.

Before administering ZOSTAVAX® (Zoster Vaccine Live), please read the Prescribing Information. The Patient Information also is available.

VACC-1133787-0012 03/17